Turning Point Therapeutics (Turning Point Therapeutics) Financial Strength : 6 (As of Jun. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Turning Point Therapeutics Financial Strength?

Turning Point Therapeutics has the Financial Strength Rank of 6.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Turning Point Therapeutics's interest coverage with the available data. Turning Point Therapeutics's debt to revenue ratio for the quarter that ended in Jun. 2022 was 10.37. As of today, Turning Point Therapeutics's Altman Z-Score is 43.98.

Competitive Comparison of Turning Point Therapeutics's Financial Strength

For the Biotechnology subindustry, Turning Point Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Turning Point Therapeutics's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turning Point Therapeutics's Financial Strength distribution charts can be found below:

* The bar in red indicates where Turning Point Therapeutics's Financial Strength falls into.

Turning Point Therapeutics Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Turning Point Therapeutics's Interest Expense for the months ended in Jun. 2022 was $0.00 Mil. Its Operating Income for the months ended in Jun. 2022 was $-124.36 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.89 Mil.

Turning Point Therapeutics's Interest Coverage for the quarter that ended in Jun. 2022 is

GuruFocus does not calculate Turning Point Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Turning Point Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Turning Point Therapeutics's Debt to Revenue Ratio for the quarter that ended in Jun. 2022 is

Debt to Revenue Ratio	=	Total Debt (Q: Jun. 2022 )			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(4.047	+	0.89)	/	0.476
	=	10.37

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Turning Point Therapeutics has a Z-score of 43.98, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 43.98 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Turning Point Therapeutics (NAS:TPTX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Turning Point Therapeutics has the Financial Strength Rank of 6.

Turning Point Therapeutics Financial Strength Related Terms

Thank you for viewing the detailed overview of Turning Point Therapeutics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.

Turning Point Therapeutics (Turning Point Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turning Point Therapeutics Inc (NAS:TPTX) » Definitions » Financial Strength

Comparable Companies

Traded in Other Exchanges

N/A

Address

10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.tptherapeutics.com

Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.

Executives

Paolo Tombesi	officer: EVP & Chief Financial Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Steve M Sabus	officer: SVP & Chief Commercial Officer	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Brian Sun	officer: SVP & General Counsel	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Mohammad Hirmand	officer: EVP and Chief Medical Officer	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Athena Countouriotis	director, officer: President & CEO	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Siegfried Reich	officer: EVP & Chief Scientific Officer	10505 ROSELLE STREET SAN DIEGO CA 92121
Andrew John Partridge	officer: EVP & Chief Commercial Officer	C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109
Annette North	officer: EVP, General Counsel & Secty.	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Van Hoose Kyri K.	officer: Principal Accounting Officer	C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Brian Lee Baker	officer: VP of Finance and Admin.	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Yi Larson	officer: EVP & Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Jingrong Jean Cui	director, 10 percent owner, officer: Chief Scientific Officer	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428